Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD: Case 1

home / case-based-peer-perspectives / metastatic-melanoma2-case-1

Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD

Jason Luke, MD: Factors to Consider When Determining Treatment

EP. 1: Jason Luke, MD: Factors to Consider When Determining Treatment

August 16th 2016

Watch

Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatment

EP. 2: Jeffrey Weber, MD, PhD: Factors to Consider When Determining Treatment

August 16th 2016

Watch

Jeffrey Weber, MD, PhD: The Impact of Moderate Level of Disease Burden on Response to Targeted Therapy

EP. 3: Jeffrey Weber, MD, PhD: The Impact of Moderate Level of Disease Burden on Response to Targeted Therapy

August 16th 2016

Watch

Jason Luke, MD: The Impact of Moderate Level of Disease Burden on Response to Targeted Therapy

EP. 4: Jason Luke, MD: The Impact of Moderate Level of Disease Burden on Response to Targeted Therapy

August 16th 2016

Watch

Jeffrey Weber, MD, PhD: Durability of a Response to Targeted Therapy Combination

EP. 5: Jeffrey Weber, MD, PhD: Durability of a Response to Targeted Therapy Combination

August 16th 2016

Watch

Jason Luke, MD: Durability of a Response to Targeted Therapy Combination

EP. 6: Jason Luke, MD: Durability of a Response to Targeted Therapy Combination

August 16th 2016

Watch

Jeffrey Weber, MD, PhD: The Impact of BRAF/MEK Inhibitors in Melanoma

EP. 7: Jeffrey Weber, MD, PhD: The Impact of BRAF/MEK Inhibitors in Melanoma

August 16th 2016

Watch

Jeffrey Weber, MD, PhD: Second-Line Therapy

EP. 8: Jeffrey Weber, MD, PhD: Second-Line Therapy

August 16th 2016

Watch

Jason Luke, MD: The Impact of BRAF/MEK Inhibitors in Melanoma

EP. 9: Jason Luke, MD: The Impact of BRAF/MEK Inhibitors in Melanoma

August 16th 2016

Watch

Jason Luke, MD: Second-Line Therapy

EP. 10: Jason Luke, MD: Second-Line Therapy

August 16th 2016

Watch